Alnylam gains, Ionis down on updated data for ATTR candidates

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) gained $12.50 (10%) to $133.59 on Thursday, while Ionis lost $5.94 (10%) to $51.82 after the companies reported detailed Phase III data for their candidates to treat familial amyloidotic polyneuropathy (FAP), a form of transthyretin (TTR) amyloidosis.

Alnylam and the Sanofi Genzyme unit of Sanofi (Euronext:SAN; NYSE:SNY) announced data from the Phase III APOLLO trial of patisiran (ALN-TTR02). Ionis reported data from the Phase III NEURO-TTR trial of inotersen (IONIS-TTRRx)...